How is cancer pain treated?
Successful Whole-exome Sequencing From A Prostate Cancer Bone Metastasis Biopsy
Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Translational Med 2011; 3: 111ra21.
Wagle N, Berger MF, Davis MJ, Blumenstiel B, Defelice M, Pochanard P et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discovery 2012; 2: 82–93.
de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995–2005.
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187–1197.
Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487: 239–243.
Mehra R, Kumar-Sinha C, Shankar S, Lonigro RJ, Jing X, Philips NE et al. Characterization of bone metastases from rapid autopsies of prostate cancer patients. Clin Cancer Res 2011; 17: 3924–3932.
Febbo PG, Thorner A, Rubin MA, Loda M, Kantoff PW, Oh WK et al. Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. Clin Cancer Res 2006; 12: 152–158.
Fisher S, Barry A, Abreu J, Minie B, Nolan J, Delorey TM et al. A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. Genome Biol 2011; 12: R1.
Drier Y, Lawrence MS, Carter SL, Stewart C, Gabriel SB, Lander ES et al. Somatic rearrangements across cancer reveal classes of samples with distinct patterns of DNA breakage and rearrangement-induced hypermutability. Genome Res 2013; 23: 228–235.
Van Allen E, Wagle N, Kryukov G, Ramos A, Getz G, Garraway L . A heuristic platform for clinical interpretation of cancer genome sequencing data. J Clin Oncol 2012; (suppl; abstr 10502).
Quayle SN, Lee JY, Cheung LW, Ding L, Wiedemeyer R, Dewan RW et al. Somatic mutations of PIK3R1 promote gliomagenesis. PloS One 2012; 7: e49466.
Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39: D945–D950.
Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012; 44: 685–689.
Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP). Seattle, WA, USA 2012.
Farrugia DJ, Agarwal MK, Pankratz VS, Deffenbaugh AM, Pruss D, Frye C et al. Functional assays for classification of BRCA2 variants of uncertain significance. Cancer Res 2008; 68: 3523–3531.
Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011; 306 (14): 1557–1565.
Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123–134.
Nakabayashi M, Werner L, Courtney KD, Buckle G, Oh WK, Bubley GJ et al. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU Int 2012; 110: 1729–1735.
Van Allen EM, Pomerantz M . Moving toward personalized medicine in castration-resistant prostate cancer. Urol Clinics North Am 2012; 39: 483–490.
Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011; 19: 575–586.
Spritzer CE, Alfonso PD, Vinson EN, Turnbull JD, Morris KK, Foye A et al. Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer - factors affecting diagnostic success. Radiology 2013; 269: 816–823.
Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 2011; 19: 664–678.
Ateeq B, Tomlins SA, Laxman B, Asangani IA, Cao Q, Cao X et al. Therapeutic targeting of SPINK1-positive prostate cancer. Sci Translational Med 2011; 3: 72ra17.
Cibulskis K, McKenna A, Fennell T, Banks E, DePristo M, Getz G . ContEst: estimating cross-contamination of human samples in next-generation sequencing data. Bioinformatics 2011; 2718: 2601–2602.
McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 20: 1297–1303.
Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 2013; 31: 213–219.
What To Know About Lung Adenocarcinoma
A lung adenocarcinoma is a type of non-small cell lung cancer (NSCLC) that begins in the glandular cells of the lungs. Depending on the stage, this can be a serious illness. However, treatment can improve a person's outcome.
According to the American Cancer Society (ACS), lung cancer is the second most common type of cancer in both males and females.
Among lung cancer types, lung adenocarcinoma is most frequently observed. Most cancers that begin in the breast, pancreas, and prostate also are adenocarcinomas.
Read on to learn more about lung adenocarcinoma, its symptoms, treatment, and outlook.
There are two predominant types of lung cancer:
The ACS reports that NSCLC is much more common, making up 80% to 85% of all lung cancers.
Lung adenocarcinoma is a type of NSCLC, with the two others being squamous cell lung carcinoma and large cell carcinoma. About 40% of all lung cancers are NSCLC, according to the National Cancer Institute (NCI).
It begins in the glandular cells, which create and release fluids such as mucus and line the walls of your alveoli, the tiny air sacs in your lungs. When they turn cancerous, they begin to grow abnormally. They're often found on the outer parts of the lungs.
Adenocarcinoma of the lung can be further divided into different subtypes based on factors like:
Early on, a person with NSCLC may not experience symptoms. Once symptoms appear, they usually include a cough that does not go away. NSCLC can also cause chest pain when taking a deep breath, coughing, or laughing.
Other symptoms include:
The outlook for people with lung cancer is better when the cancer is found and treated early. If you develop any of the symptoms above, make an appointment with a doctor. They can perform tests to help find what's causing your symptoms.
NSCLC tends to form in the cells along the outer part of the lungs. In the precancerous stage, cells undergo genetic changes that cause the abnormal cells to grow faster.
Further genetic alterations may lead to changes that help the cancer cells grow and form a mass or tumor. Cells that make up a lung cancer tumor can break off and spread to other parts of the body.
The growth of lung adenocarcinoma happens in the following stages:
Depending on the stage of diagnosis, lung adenocarcinoma can be a serious illness. The more the cancer has spread, the more ongoing treatment you will need.
That said, a variety of factors can affect your outlook with adenocarcinoma of the lung. These include:
Having a family history of lung cancer raises your chance of developing it yourself. Certain genetic mutations can also predispose you to it.
Other risk factors include:
To diagnose lung adenocarcinoma of the lung, your doctor will first request your medical history. They'll ask about the symptoms you're having if you currently or have previously smoked and if you have a family history of lung cancer.
They'll then perform a physical examination. At this time, they'll get your vital signs and will listen to your lungs as you breathe.
The tests that may be ordered to help diagnose adenocarcinoma of the lung are:
A lung biopsy is the only way to definitively diagnose adenocarcinoma of the lung. If the tests above raise suspicions of lung cancer, your doctor will request that a biopsy be collected from the affected area and examined under a microscope to look for signs of cancer.
This tissue can also be tested for proteins or genetic changes associated with adenocarcinoma of the lung. If present, they can affect outlook and may also be targets for treatments like targeted therapy and immunotherapy.
An effective treatment for non-small cell adenocarcinoma depends on the cancer's stage. It may include:
Surgery to remove all or only part of the lung is often required if the cancer has not spread. Other treatments are more likely to be needed if the cancer has spread.
Is lung adenocarcinoma cancer curable?While it's not impossible to cure lung adenocarcinoma, this is often difficult because the condition is commonly diagnosed at an advanced stage.
Overall, the 5-year survival rate for NSCLC depends on whether the cancer has spread:
That said, research suggests that people with lung adenocarcinoma may have a slightly higher 5-year survival rate compared to those with other types of lung cancer (32.3% vs 25.4%).
People with two subtypes of adenocarcinoma of the lung, adenocarcinoma in situ and minimally invasive adenocarcinoma have a better outcome, especially when the cancer is treated early with surgery. If surgery completely removes the cancer, the 5-year survival rate approaches 100%.
That said, survival rates are calculated based on data from many people with NSCLC and do not account for individual factors or recent advances in diagnosis and treatment. Overall, it's best to discuss your individual outlook with your care team.
A lung adenocarcinoma is a form of NSCLC originating in the glandular cells of the lungs. Depending on its stage, this can be potentially life threatening. There are treatment options available that may lead to better outcomes.
Doctors and researchers also continue to develop newer, more effective treatments for adenocarcinoma of the lung. These can include new targeted therapy or immunotherapy drugs or new ways to use existing treatments.
Before being used on a larger scale, these new treatments need to be tested in clinical trials. If you're interested in taking part in a clinical trial, talk with your care team. They can help you to find one that you would be a good candidate for.
You can also consider looking at clinical trials supported by the NCI. The LUNGevity Foundation also provides a clinical trial matching service via the phone or an online search tool.
Read this article in Spanish.
Georgia WWII Hero's Grave Inspires Songwriter Ballad Decades After Soldier Killed In Combat
Join Fox News for access to this content
Plus special access to select articles and other premium content with your account - free of charge.
By entering your email and pushing continue, you are agreeing to Fox News' Terms of Use and Privacy Policy, which includes our Notice of Financial Incentive.Please enter a valid email address.
Having trouble? Click here.FIRST ON FOX: A World War II hero from backwoods Georgia inspires Americans today even from the grave.
The story of U.S. Army PFC Ervin O. Jones is worthy of a song.
Craig Gleason, a Georgia songwriter, penned "The Ballad of Ervin O. Jones" in 2014, after he and his daughter came across the soldier's headstone in a churchyard cemetery in the city of Alpharetta.
AMERICAN WORLD WAR II HEROES, ADOPTED IN 'FACES OF MARGRATEN' PROJECT BY 'GRATEFUL' DUTCH PEOPLE
"It's a powerful story, man. It's powerful," Gleason said Sunday in a telephone interview with Fox News Digital.
Gleason, in turn, teaches the art of songwriting to struggling veterans who attend Warrior Week each month at Camp Southern Ground in Fayetteville, Georgia.
U.S. Army PFC Ervin O. Jones of Alpharetta, Georgia, was just 20 years old when he was killed in the Battle of Okinawa in 1945. Seven decades later, his Georgia gravestone inspired musician Craig Gleason to write "The Ballad of Ervin O. Jones." (Jones Family/Craig Gleason)
Grammy Award-winning musician Zac Brown founded the camp in 2011. Gleason is a former coordinator for the Nashville Songwriters Association.
Gleason looked at a church cemetery near his home in Alpharetta as an opportunity to learn about, and teach his daughter, then aged 12, about local history.
"When you homeschool your children, you use real-life experiences, every place you go and everyone you meet, as a learning experience," said Gleason.
THESE 5 US MILITARY CEMETERIES IN SURPRISING NATIONS ARE LASTING REMINDERS OF AMERICA'S GLOBAL SACRIFICE
It's the same skill used by songwriters to take everyday experiences and interpret them for others through the human gift of music.
"I told Audrey, you can learn a lot from these tombstones."
The Gleasons found out about a hometown hero buried in their midst. Along the way, they earned a lesson about the grief that grips a family decades after wartime loss.
U.S. Army PFC Ervin O. Jones of Alpharetta, Georgia, was just 20 years old when he was killed during the Battle of Okinawa in 1945. His gravestone inspired musician Craig Gleason to write "The Ballad of Ervin O. Jones." (Jones Family/Craig Gleason)
PFC Jones was just 20 years old when he was killed on the island of Ieshima during the Battle of Okinawa on April 17, 1945, as Americans forces closed in on the home islands of Imperial Japan.
Gleason was haunted by the grave and was moved to write about the soldier. But he wanted to know the real story about the young man resting under the headstone near his home.
He soon learned that PFC Jones' younger brother, Curtis, was still alive and living nearby, in Canton, Georgia.
MEMORIAL DAY: IMPORTANT FACTS ABOUT THE SOLEMN AMERICAN HOLIDAY
"Curtis was living in a little trailer out in the woods and I knocked on his door and introduced myself," said Gleason. "I said, 'I'm writing a song about your brother Ervin' and asked if we could talk."
He added, "Curtis was like old-school backwoods Georgia. Real salt of the Earth. He invited me in and for the next three or four hours in his living room he pulled out artifacts, pictures and an old guitar that Ervin owned."
Turns out that Gleason and the forever-young dirt-poor Georgia farmboy shared the gift of music.
Curtis Jones, now deceased, lived his adult life with the pain of his older brother's death during World War II. PFC Ervin O. Jones was killed on the Japanese island of Ieshima on April 17, 1945. (Jones Family/Craig Gleason)
"We laughed and cried, and by the end I felt like I had become part of that family within just a few hours."
Among other things, Gleason learned that the former stranger, PFC Jones, died a hero.
"His courage and aggressiveness in this action was truly an inspiration to the officers and men in his company," his commanding officer, Capt. William B. Cooper, wrote in July 1945, in a letter addressed to the soldier's mother, Jennie.
(Here's the song below, embedded with permission from Craig Gleason, creator and copyright owner.)
One of Gleason's most painful discoveries was that Jones' parents never fully coped with the overwhelming grief they suffered upon learning of their son's death.
"Granny Jennie and Papa Harmon never mentioned Ervin, and we visited them every Sunday until they passed," PFC's nephew and his wife, John and Judy Jones, said via text message on Sunday.
"American patriots and war heroes, much like songs, grow from the most humble circumstances."
"The pain of the loss of their firstborn son Ervin never went away and they grieved until they died."
CLICK HERE TO SIGN UP FOR OUR LIFESTYLE NEWSLETTER
Gleason learned one other lesson — a powerful lesson he said he tries to pass on to aspiring musicians, veterans, everyday Americans and the people for whom he performs "The Ballad of Ervin O. Jones."
CLICK HERE TO GET THE FOX NEWS APP
He learned that American patriots and war heroes, much like songs, grow from the most humble circumstances.
Army PFC Ervin O. Jones was killed on April 17, 1945, during the Battle of Okinawa. His Georgia grave inspired musician Craig Gleason to write "The Ballad of Ervin O. Jones" seven decades later. (Jones Family/Craig Gleason and Will Lester/MediaNews Group/Inland Valley Daily Bulletin via Getty Images)
He writes, and sings, in the last lines of the ballad: "From the lowlands to the highlands / Across every stick and stone / Came heroes who gave and lost their lives / Heroes like Ervin O. Jones."
For more Lifestyle articles, visit www.Foxnews.Com/lifestyle.
Comments
Post a Comment